Litigation Details for BTG INTERNATIONAL LIMITED v. MSN PHARMACEUTICALS INC. (D.N.J. 2018)
✉ Email this page to a colleague
BTG INTERNATIONAL LIMITED v. MSN PHARMACEUTICALS INC. (D.N.J. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-02-19 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-05-30 |
| Cause | 15:1126 Patent Infringement | Assigned To | Kevin McNulty |
| Jury Demand | None | Referred To | William Clark |
| Patents | 8,822,438 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BTG INTERNATIONAL LIMITED v. MSN PHARMACEUTICALS INC.
The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for BTG INTERNATIONAL LIMITED v. MSN PHARMACEUTICALS INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-02-19 | 1 | the expiration of United States Patent No. 8,822,438 (“the ’438 patent”). …Hearing and Correct Inventorship of U.S. Patent No. 8,822,438 Pursuant to 35 U.S.C. § 256 and directed… This is a civil action for patent infringement arising under the patent laws of the United States, … THE PATENT-IN-SUIT 10. The ’438 patent, entitled “Methods and Compositions…the ’438 patent are unpatentable. The PTAB cannot issue a certificate cancelling the patent claims until | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
